Patents Assigned to SYNTIMMUNE, INC.
  • Humanized affinity matured anti-FcRn antibodies
    Patent number: 10822417
    Abstract: Provided herein are recombinant antibodies and antigen-binding portions thereof useful for binding to FcRn and blocking binding of FcRn to human serum albumin. The FcRn-binding proteins can be used to treat a variety of disorders including acute and chronic toxic exposure.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: November 3, 2020
    Assignee: Syntimmune, Inc.
    Inventors: Laurence J. Blumberg, Richard S. Blumberg, Susan D. Jones, Derry Roopenian, Robert George E. Holgate, Timothy D. Jones, Arron R. Hearn
  • Humanized affinity matured anti-FcRn antibodies
    Patent number: 10626175
    Abstract: Provided herein are recombinant antibodies and antigen-binding portions thereof useful for binding to FcRn and blocking binding of FcRn to IgG Fc. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: April 21, 2020
    Assignee: SYNTIMMUNE, INC.
    Inventors: Laurence J. Blumberg, Richard S. Blumberg, Susan Dana Jones, Derry Roopenian, Robert George Edward Holgate, Timothy David Jones, Arron Robert Hearn